High mobility group A-interacting proteins in cancer: Focus on chromobox protein homolog 7, homeodomain interacting protein kinase 2 and PATZ

Journal of Nucleic Acids Investigation

Volumn 3, Issue 1, 2012, Pages

  Fedele, Monica ^a   Pierantoni, Giovanna Maria ^a   Pallante, Pierlorenzo ^a   Fusco, Alfredo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cancer; CBX7; High mobility group; HIPK2; PATZ1

Indexed keywords

CHROMOBOX PROTEIN HOMOLOG 7; HIGH MOBILITY GROUP A PROTEIN; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; PROTEIN PATZ; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; COMPLEX FORMATION; DISEASE ASSOCIATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE REARRANGEMENT; HUMAN; MALIGNANT TRANSFORMATION; NEOPLASM; NONHUMAN; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW;

EID: 84868014047     PISSN: None     EISSN: 20356005     Source Type: Journal    
DOI: 10.4081/jnai.2012.e1     Document Type: Review

References (89)

1. Hock R, Furusawa T, Ueda T, Bustin M. HMG chromosomal proteins in development and disease. Trends Cell Biol 2007; 17:72-9.
2. Sgarra R, Zammitti S, Lo Sardo A, et al. HMGA molecular network: From transcriptional regulation to chromatin remodeling. Bioch Bioph Acta 2010;1799:3747.
3. Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996;13:2439-46.
4. Rogalla P, Drechsler K, Frey G, et al. HMGIC expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol 1996; 149:775-9.
5. Zhou X, Benson KF, Przybysz K, et al. Genomic structure and expression of the murine Hmgi-c gene. Nucleic Acids Res 1996;24:4071-7.
6. Rommel B, Rogalla P, Jox A, et al. HMGI-C, a member of the high mobility group family of proteins, is expressed in hematopoietic stem cells and in leukemic cells. Leuk Lymphoma 1997;26:603-7.
7. Nishino J, Kim I, Chada K, Morrison SJ. Hmga2 promotes neural stem cell selfrenewal in young but not old mice by reducing p16Ink4a and p19Arf Expression. Cell 2008;135:227-39.
8. Pfannkuche K, Summer H, Li O, et al. The high mobility group protein HMGA2: a coregulator of chromatin structure and pluripotency in stem cells? Stem Cell Rev 2009;5:224-30.
9. Fusco A, Fedele M. Roles of the HMGA proteins in cancer. Nat Rev Cancer 2007;7: 899-910.
10. Hess JL. Chromosomal translocations in benign tumors: the HMGI proteins. Am J Clin Pathol 1998 109:251-61.
11. Bullerdiek J, Rommel B. Diagnostic and molecular implications of specific chromosomal translocations in mesenchymal tumors. Histol Histopathol 1999;14:1165-73.
12. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007;315:1576-9.
13. Hebert C, Norris K, Scheper MA, et al. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 2007;6:5.
14. Boyerinas B, Park SM, Shomron N, et al. Identification of let-7-regulated oncofetal genes. Cancer Res 2008;68:2587-91.
15. Kaddar T, Rouault JP, Chien WW, et al. Two new miR-16 targets: caprin-1 and HMGA1, proteins implicated in cell proliferation. Biol Cell 2009;101:511-24.
16. Wei JJ, Wu X, Peng Y, et al. Regulation of HMGA1 expression by microRNA-296 affects prostate cancer growth and invasion. Clin Cancer Res 2011;17:1297-305.
17. Scala S, Portella G, Fedele M, et al. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci USA 2000;97:4256-61.
18. Wood LJ, Maher JF, Bunton TE, Resar LM. The oncogenic properties of the HMG-I gene family. Cancer Res 2000;60:4256-61.
19. Fedele M, Fusco A. HMGA and cancer. Biochim Biophys Acta 2010;1799:48-54.
20. Sgarra R, Tessari MA, Di Bernardo J, et al. Discovering high mobility group A molecular partners in tumour cells. Proteomics 2005;5:1494-506.
21. Pierantoni GM, Esposito F, Giraud S, et al. Identification of new high mobility group A1 associated proteins. Proteomics 2007;7: 3735-42.
22. Sgarra R, Furlan C, Zammitti S, et al. Interaction proteomics of the HMGA chromatin architectural factors. Proteomics 2008;8:4721-32.
23. Pierantoni GM, Fedele M, Pentimalli F, et al. High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth. Oncogene 2001;20:6132-41.
24. Pierantoni GM, Rinaldo C, Esposito F, et al. High Mobility Group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. Cell Death Differ 2006;13:1554-63.
25. Winter N, Nimzyk R, Bösche C, et al. Chromatin immunoprecipitation to analyze DNA binding sites of HMGA2. PLoS One 2011;6:e18837.
26. Himes SR, Reeves R, Attema J, et al. The role of high-mobility group I(Y) proteins in expression of IL-2 and T cell proliferation. J Immunol 2000;164:3157-68.
27. Yie J, Merika M, Munshi N, et al. The role of HMG I(Y) in the assembly and function of the IFN-beta enhanceosome. EMBO J 1999;18:3074-89.
28. Pentimalli F, Palmieri D, Pacelli R, et al. HMGA1 protein is a novel target of the ATM kinase. Eur J Cancer 2008;44:2668-79.
29. Palmieri D, Valentino T, D'Angelo D, et al. HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents. Oncogene 2011;30:3024-35.
30. Forzati F, Federico A, Pallante P, et al. CBX7 is a tumor suppressor in mouse and human. J Clin Invest 2012; doi: 10.1172/ JCI58620. [Epub ahead of print]
31. Bouallaga I, Massicard S, Yaniv M, Thierry F. An enhanceosome containing the Jun B/Fra-2 heterodimer and the HMG-I(Y) architectural protein controls HPV 18 transcription. EMBO Rep 2000;1:422-7.
32. Di Agostino S, Fedele M, Chieffi P, et al. Phosphorylation of high-mobility group protein A2 by Nek2 kinase during the first meiotic division in mouse spermatocytes. Mol Biol Cell 2004;15:1224-32.
33. Fedele M, Benvenuto G, Pero R, et al. A novel member of the BTB/POZ family, PATZ, associates with the RNF4 RING finger protein and acts as a transcriptional repressor. J Biol Chem 2000;275:7894-901.
34. Nagpal S, Ghosn C, DiSepio D, et al. Retinoid-dependent recruitment of a histone H1 displacement activity by retinoic acid receptor. J Biol Chem 1999;274:22563-8.
35. Fedele M, Visone R, De Martino I, et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 2006;9:459-71.
36. Esposito F, Pierantoni GM, Battista S, et al. Interaction between HMGA1 and retinoblastoma protein is required for adipocyte differentiation. J Biol Chem 2009;284: 25993-6004.
37. Frasca F, Rustighi A, Malaguarnera R, et al. HMGA1 inhibits the function of p53 family members in thyroid cancer cells. Cancer Res 2006;66:2980-9.
38. Schuettengruber B, Chourrout D, Vervoort M, et al. Genome regulation by polycomb and trithorax proteins. Cell 2007;128:735-45.
39. Scott CL, Gil J, Hernando E, et al. Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad Sci USA 2007;104:5389-94.
40. Wu JI, Lessard J, Crabtree GR. Understanding the words of chromatin regulation. Cell 2009;136:200-6.
41. Li Q, Wang X, Lu Z, et al. Polycomb CBX7 directly controls trimethylation of histone H3 at lysine 9 at the p16 locus. PLoS One 2010;5:e13732.
42. Bernstein E, Duncan EM, Masui O, et al. Mouse polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. Mol Cell Biol 2006;26:2560-9.
43. Lund AH, van Lohuizen M. Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 2004;16:239-46.
44. Pallante P, Federico A, Berlingieri MT, et al. Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res 2008;68: 6770-8.
45. Pallante P, Terracciano L, Carafa V, et al. The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. Eur J Cancer 2010;46:2304-13.
46. Karamitopoulou E, Pallante P, Zlobec I, et al. Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur J Cancer 2010;46:1438-44.
47. Hinz S, Kempkensteffen C, Christoph F, et al. Expression parameters of the polycomb group proteins BMI1, SUZ12, RING1 and CBX7 in urothelial carcinoma of the bladder and their prognostic relevance. Tumour Biol 2008;29:323-9.
48. Mansueto G, Forzati F, Ferraro A, et al. Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein. Genes Cancer 2010;1:210-24.
49. Jiang Z, Guo J, Xiao B, et al. Increased expression of miR-421 in human gastric carcinoma and its clinical association. J Gastroenterol 2010;45:17-23.
50. Federico A, Pallante P, Bianco M, et al. Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. Cancer Res 2009;69: 7079-87.
51. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
52. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-42.
53. Boye K, Maelandsmo GM. S100A4 and metastasis: a small actor playing many roles. Am J Pathol 2010;176:528-35.
54. Shevde LA, Das S, Clark DW, Samant RS. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med 2010;10: 71-81.
55. Bernard D, Martinez-Leal JF, Rizzo S, et al. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene 2005;24: 5543-51.
56. Gil J, Bernard D, Martínez D, Beach D. Polycomb CBX7 has a unifying role in cellular lifespan. Nat Cell Biol 2004;6:67-72.
57. Ma Y, Fiering S, Black C, et al. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A 2007;104:4089-94.
58. Kim YH, Choi CY, Lee SJ, Conti MA, Kim Y. Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors. J Biol Chem 1998;273:25875-9.
59. Giancotti V, Pani B, D'Andrea P, et al. Elevated levels of a specific class of nuclear phosphoproteins in cells transformed with v-ras and v-mos oncogenes and by cotransfection with c-myc and polyoma middle T genes. EMBO J 1987;6:1981-7.
60. Zhang Q, Wang Y. Homeodomain-interacting protein kinase-2 (HIPK2) phosphorylates HMGA1a at Ser-35, Thr-52, and Thr-77 and modulates its DNA binding affinity. J Proteome Res 2007;6:4711-9.
61. Okuda H, Manabe T, Yanagita T, et al. Novel interaction between HMGA1a and StIP1 in murine terminally differentiated retina. Mol Cell Neurosci 2006;33:81-7.
62. Trapasso F, Aqeilan RI, Iuliano R, et al. Targeted disruption of the murine homeodomain-interacting protein kinase-2 causes growth deficiency in vivo and cell cycle arrest in vitro. DNA Cell Biol 2009;28:161-7.
63. Iacovelli S, Ciuffini L, Lazzari C, et al. HIPK2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage. Cell Prolif 2009;42:373-84.
64. D'Orazi G, Cecchinelli B, Bruno T, et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 2002;4:11-9.
65. Hofmann TG, Moller A, Sirma H, et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 2002; 4:1-10.
66. Cecchinelli B, Porrello A, Lazzari C, et al. Ser58 of mouse p53 is the homologue of human Ser46 and is phosphorylated by HIPK2 in apoptosis. Cell Death Differ 2006;13:1994-7.
67. Hofmann TG, Stollberg N, Schmitz ML, Will H. HIPK2 regulates transforming growth factor-beta-induced c-Jun NH(2)-terminal kinase activation and apoptosis in human hepatoma cells. Cancer Res 2003;63:8271-7.
68. Rui Y, Xu Z, Lin S, et al. Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation. EMBO J 2004;23:4583-94.
69. Esposito F, Tornincasa M, Chieffi P, et al. High-mobility group A1 proteins regulate p53-mediated transcription of Bcl-2 gene. Cancer Res 2010;70:5379-88.
70. Pierantoni GM, Rinaldo C, Mottolese M, et al. High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J Clin Invest 2007;117:693-702.
71. Wee HJ, Voon DC, Bae SC, Ito Y. PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis. Blood 2008;112:3777-87.
72. Pierantoni GM, Bulfone A, Pentimalli F, et al. The homeodomain-interacting protein kinase 2 gene is expressed late in embryogenesis and preferentially in retina, muscle, and neural tissues. Biochem Biophys Res Commun 2002;290:942-7.
73. Li XL, Arai Y, Harada H, et al. Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription. Oncogene 2007;26:7231-9.
74. Lavra L, Rinaldo C, Ulivieri A, et al. The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas. PLoS One 2011;6:e20665.
75. Huang H, Reed CP, Mordi A, et al. Frequent deletions within FRA7G at 7q312 in invasive epithelial ovarian cancer. Genes Chromosomes Cancer 1999;24:48-55.
76. Kobayashi A, Yamagiwa H, Hoshino H, et al. A combinatorial code for gene expression generated by transcription factor Bach2 and MAZR (MAZ-related factor) through the BTB/POZ domain. Mol Cell Biol 2000;20:1733-46.
77. Mastrangelo T, Modena P, Tornielli S, et al. A novel zinc finger gene is fused to EWS in small round cell tumor. Oncogene 2000;19: 3799-804.
78. Morii E, Oboki K, Kataoka TR, et al. Interaction and cooperation of mi transcription factor (MITF) and myc-associated zinc-finger protein-related factor (MAZR) for transcription of mouse mast cell protease 6 gene. J Biol Chem 2002;277:8566-71.
79. Pero R, Lembo F, Palmieri EA, et al. PATZ attenuates the RNF4-mediated enhancement of androgen receptor-dependent transcription. J Biol Chem 2002;277:3280-5.
80. Bilic I, Koesters C, Unger B, et al. Negative regulation of CD8 expression via Cd8 enhancer-mediated recruitment of the zinc finger protein MAZR. Nat Immunol 2006;7:392-400.
81. Sakaguchi S, Hombauer M, Bilic I, et al. The zinc-finger protein MAZR is part of the transcription factor network that controls the CD4 versus CD8 lineage fate of double-positive thymocytes. Nat Immunol 2010;11:442-8.
82. Modena P, Testi MA, Facchinetti F, et al. UQCRH gene encoding mitochondrial Hinge protein is interrupted by a translocation in a soft-tissue sarcoma and epigenetically inactivated in some cancer cell lines. Oncogene 2003;22:4586-93.
83. Burrow AA, Williams LE, Pierce LC, Wang YH. Over half of breakpoints in gene pairs involved in cancer-specific recurrent translocations are mapped to human chromosomal fragile sites. BMC Genomics 2009;10:59.
84. Tian X, Sun D, Zhang Y, Zhao S, Xiong H, Fang J. Zinc finger protein 278, a potential oncogene in human colorectal cancer. Acta Biochim Biophys Sin (Shanghai) 2008;40: 289-96.
85. Tritz R, Mueller BM, Hickey MJ, et al. siRNA Down-regulation of the PATZ1 Gene in Human Glioma Cells Increases Their Sensitivity to Apoptotic Stimuli. Cancer Ther 2008;6:865-76.
86. Fedele M, Franco R, Salvatore G, et al. PATZ1 gene has a critical role in the spermatogenesis and testicular tumours. J Pathol 2008;215:39-47.
87. Yang WL, Ravatn R, Kudoh K, Alabanza L, Chin KV. Interaction of the regulatory subunit of the cAMP-dependent protein kinase with PATZ1 (ZNF278). Biochem Biophys Res Commun 2010;391:1318-23.
88. Tortora G, Pepe S, Bianco C, et al. The RI alpha subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells. Oncogene 1994;9:3233-40.
89. Tortora G, Pepe S, Bianco C, et al. Differential effects of protein kinase A sub-units on Chinese-hamster-ovary cell cycle and proliferation. Int J Cancer 1994;59:712-6.